SightfileU.S. market data from official filings

TELIX PHARMACEUTICAL LTD (TLX)

Name: TELIX PHARMACEUTICAL LTD (TLX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0002007191 · EDGAR filings · Updated 2026-07-21

TELIX PHARMACEUTICAL LTD (TLX) has reported institutional ownership of 0.8%, with 38 institutional managers holding positions valued at $24.5M per the latest 13F reporting period.

Institutional ownership

0.8%

Institutional managers

Reported 13F value

$24.5M

Latest updates

2026-07-21 — Foreign issuer report (6-K) filed
2026-07-02 — Foreign issuer report (6-K) filed
2026-05-21 — Foreign issuer report (6-K) filed
2026-05-18 — Initial insider ownership filed (Form 3)
2026-05-18 — Initial insider ownership filed (Form 3)
2026-05-18 — Initial insider ownership filed (Form 3)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, TELIX PHARMACEUTICAL LTD has 38 institutional holders and institutional ownership of 0.8%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 3 reporting insiders, with a net reported value of $0.

Related companies

SANARA MEDTECH INC (SMTI) · VERRICA PHARMACEUTICALS INC (VRCA) · LIPOCINE INC NEW (LPCN) · GYRE THERAPEUTICS INC (GYRE) · GENELUX CORPORATION (GNLX) · INOTIV INC (NOTVQ)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.